<DOC>
	<DOC>NCT01824264</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy, tolerability and short-term safety of LIK066 to support dose selection for phase 3.</brief_summary>
	<brief_title>Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1. Confirmed diagnosis of T2DM by standard criteria 2. Drugnaïve patients, defined as patients not having received any antidiabetic medication previously, 3. Currently untreated patients , who, after the diagnosis of T2DM, have received antidiabetic medication for not more than 12 consecutive weeks, and have not received any antidiabetic treatment within 12 weeks prior to Visit 1 4. Patients being treated with monotherapy for at least 8 consecutive weeks prior to Visit 1 with the following OADs: metformin, dipeptidyl peptidase4 inhibitors (DPP4i), SU, glinide, alphaglucosidase inhibitor (AGI) 5. HbA1c ≥ 7 to ≤ 10.5% at Visit 1 for drugnaïve/currently untreated patients 6. HbA1c ≥ 7 to ≤ 9.5% at Visit 1 for patients treated with OAD monotherapy 7. HbA1c ≥ 7 to ≤ 10.5% at Visit 199 for ALL patients 8. Age: ≥18 and ≤ 75 years old at Visit 1 9. BMI ≥22 to ≤45 kg/m2 at Visit 1 1. FPG ≥270 mg/dl (15 mmol/L) for drugnaïve/currently untreated patients or ≥240 mg/dl (13.3 mmol/L) for patients on OAD monotherapy at Visit 1 2. Insulin treatment &gt;4 consecutive weeks in the last 6 months, corticosteroid use &gt;7 days in the last 8 weeks, use of growth hormones in the last 6 months, or use of weight control products &gt; 4 weeks in the last 6 months 3. History of acute metabolic complications, CV disease, type 1 diabetes mellitus, hepatic disorders, pancreatitis, chronic diarrhea 4. Significant lab abnormalities such as TSH outside of normal range, UACR&gt;300 mg/g creatinine, eGFR &lt;60 ml/min/1.73m2, hemoglobin &lt;12 g/L in men and &lt;11 g/L in women, hematuria 5. ECG abnormalities including AV block, long QT syndrome or QTc&gt;450 msec for men and &gt;470 msec for women 6. History of malignancy 7. Women of childbearing potential not using effective methods of contraception Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Type 2 Diabetes mellitus, SGLT inhibitors, dose-response</keyword>
</DOC>